"Pearson’s next suggestion was even more daring: Cut research and development spending, the heart of most drug firms, to the bone. “We had a premise that most R&D didn’t give good return to shareholders,” says Pearson. Instead, the company should favour M&A over R&D, buying established treatments that made enough money to matter, but not enough to attract the interest of Big Pharma or generic drug makers"
TLDR:
Cut R&D, buy successful but smaller drugs and then because of no competition make a killing by jacking up prices.
This firm and its nasty business model of profiteering off the backs of sick desperate people, deserve to die. They are no better than vultures that feed on the dying.
It contained the all important paragraph:
"Pearson’s next suggestion was even more daring: Cut research and development spending, the heart of most drug firms, to the bone. “We had a premise that most R&D didn’t give good return to shareholders,” says Pearson. Instead, the company should favour M&A over R&D, buying established treatments that made enough money to matter, but not enough to attract the interest of Big Pharma or generic drug makers"
TLDR: Cut R&D, buy successful but smaller drugs and then because of no competition make a killing by jacking up prices.
This firm and its nasty business model of profiteering off the backs of sick desperate people, deserve to die. They are no better than vultures that feed on the dying.